<DOC>
	<DOCNO>NCT02724878</DOCNO>
	<brief_summary>This research study study combination Atezolizumab Bevacizumab possible treatment Advanced Non-Clear Cell Kidney Cancer .</brief_summary>
	<brief_title>Study Atezolizumab + Bevacizumab Patients With Advanced Non-Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description>This research study Phase II clinical trial . In research investigator study combination Atezolizumab Bevacizumab . Participants receive vascular endothelial target therapy immunotherapy . The FDA ( U.S. Food Drug Administration ) approve Atezolizumab Advanced Non-Clear Cell Kidney Cancer , approve us . The FDA approve Bevacizumab Interferon ( IFNα ) treatment option Advanced Kidney Cancer .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Unresectable advance metastatic nonclear cell renal cell carcinoma include limit : Papillary renal cell carcinoma , type Unclassified renal cell carcinoma Translocation renal cell carcinoma Chromophobe renal cell carcinoma Collecting duct renal cell carcinoma Medullary renal cell carcinoma Clear cell renal cell carcinoma histology ≥ 20 % sarcomatoid feature eligible . Other nonclear cell histology include need discuss Principal Investigator . Request formalinfixed , paraffinembedded ( FFPE ) archival tumor specimens available willingness participant undergo mandatory fresh tumor biopsy unless determine medically unsafe feasible . Participants available archival tumor tissue require undergo fresh tumor biopsy baseline . A note study team provide document availability tissue . The archival specimen contain adequate viable tumor tissue . The specimen may consist tissue block ( prefer contain high grade tumor ) least 30 unstained serial section . Fineneedle aspiration , brushing , cell pellet pleural effusion , bone marrow aspirate/biopsy acceptable . Fresh tumor biopsy progression require case patient experience relapse initial response medically safe . Measurable disease define Response Evaluation Criteria In Solid Tumors version 1.1 . Eastern Cooperative Oncology Group performance status ≤ 2 . Adequate hematologic endorgan function define follow laboratory result obtain within 28 day prior first study treatment : Absolute neutrophil count ≥ 1500 cells/uL . Lymphocyte count ≥ 500/uL . Platelet count ≥ 100,000/uL . Hemoglobin ≥ 9 g/dL ( patient may transfuse meet criterion ) . Aspartate aminotransferase alanine aminotransferase ≤ 2.5 x upper limit normal following exception : Patients document liver metastasis aspartate aminotransferase alanine aminotransferase ≤ 5 x upper limit normal . Serum bilirubin ≤ 2.0 x upper limit normal follow exception : Patients know Gilbert 's disease serum bilirubin ≤ 3 x upper limit normal . Serum albumin &gt; 2.5 g/dL . Creatinine clearance ≥ 30 mL/min calculate CockcroftGault equation . For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use highly effective form contraception continue use 6 month last dose atezolizumab bevacizumab . Signed informed consent form . Ability capacity comply study followup procedure . Prior treatment CD137 agonist , anti cytotoxic Tlymphocyteassociated protein 4 , antiprogrammed death1 , antiprogrammed death ligand1 therapeutic antibody pathway target agent . Prior interferon alpha interleukin2 allow follow 4 week washout treatment start . Prior therapy Bevacizumab . Thrombologics event within 3 week treatment start date stability anticoagulation 2 week . Treatment systemic immunosuppressive medication include limited : prednisone , dexamethasone , cyclosporin , azathioprine , methotrexate , thalidomide , antitumor necrosis factor agent , hydroxychloroquine within 2 week first study dose . Patients receive acute , lowdose systemic immunosuppressant medication may enrol . Patients adrenal insufficiency physiologic replacement dos steroid may enrol . The use inhale , topical intraocular , intraarticular corticosteroid ormineralocorticoids allow . Radiotherapy renal cell carcinoma within 14 day first study treatment exception single fraction radiation administer palliation symptom . Known active metastasis brain , spinal cord leptomeninges unless adequately treat radiotherapy , radiosurgery , surgery stable least 4 week first study treatment document magnetic resonance image computerized tomography image ongoing requirement steroid . Malignancies renal cell carcinoma within 2 year first study treatment exception negligible risk metastasis death ( carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer , ductal carcinoma situ breast , nonmuscle invasive urothelial carcinoma , malignancy deem impact patient 5year life expectancy . Individuals history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy . In addition , individual follow cancer eligible regardless diagnose treat : cervical cancer situ , basal cell squamous cell carcinoma skin . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein . Known hypersensitivity component Atezolizumab product . History autoimmune disease include : myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegner 's granulomatosis , Sjogren 's syndrome , GuillainBarre syndrome , multiple sclerosis , type I diabetes mellitus , vasculitis , glomerulonephritis . Patients history autoimmunerelated hypothyroidism stable dose ( without adjustment 4 week first study treatment ) thyroid replacement hormone eligible . History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen image chest . History radiation pneumonitis radiation field permit . Positive test HIV ( test perform within 28 day first treatment start ) . Patients active chronic hepatitis B ( define positive hepatitis B surface antigen [ HBsAg ] test screening ) . Patients past/resolved HBV infection ( define negative HBsAg test positive antibody hepatitis B core antigen [ antiHBc ] antibody test ) eligible . A negative HBA DNA test must obtain patient positive hepatitis B core antibody prior Cycle 1 Day 1 . Active hepatitis C infection . Patients positive hepatitis C antibody test eligible PCR negative hepatitis C viral DNA . Infection require receipt therapeutic oral IV antimicrobial within 2 week first study treatment . Patients receive routine antimicrobial prophylaxis ( dental extractions/procedures ) eligible . Significant cardiovascular disease New York Heart Association class II great , myocardial infarction within previous 3 month first study treatment , unstable arrhythmia , unstable angina . Patients know coronary artery disease , congestive heart failure meeting criterion , leave ventricular ejection fraction &lt; 50 % must stable regimen optimized opinion treat physician , consultation cardiologist appropriate . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) . Antihypertensive therapy achieve parameter allow . Prior history hypertensive crisis hypertensive encephalopathy within previous 3 month first study treatment . History stroke transient ischemic attack within 3 month first study dose . Significant vascular disease ( aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month first study dose . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . Current recent use dipyramidole , ticlopidine , clopidogrel , cilostazol exclude . Aspirin ( ≤ 325 mg per day ) allow . Prophylactic anticoagulation oral parenteral anticoagulant patency venous access device indication allow . Therapeutic use lowmolecular weight heparin ( enoxaparin ) allow . History abdominal tracheoesophageal fistula gastrointestinal perforation within 6 month first study treatment . Clinical sign symptom active gastrointestinal obstruction requirement routine parenteral nutrition tube feeding . Evidence abdominal free air explain paracentesis recent surgical procedure . Serious , nonhealing dehisce wound , active ulcer . Proteinuria , demonstrate &gt; 1.5 gram protein 24hour urine collection . All patient ≥ 2+ protein dipstick urinalysis baseline must undergo 24hour urine collection protein . Major surgical procedure within 21 day first study treatment . Prior allogenic stem cell solid organ transplant . Administration live , attenuated vaccine within 4 week first study treatment . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney Cancer</keyword>
</DOC>